Posilojinjeong 5 mg (Dapagliflozin Anhydrous Mixture)
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Hanwha Pharmaceutical Co., Ltd.
MFDS item code 202005362 · Approved 2020.07.23
This product's status changed to Approval withdrawn on 2025.02.03. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used together with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be used alone or in combination with other medications. It is particularly applicable to patients who have difficulty controlling their blood sugar and have cardiovascular disease or risk factors. It is important to refer to the cautionary notes and clinical trial information presented by healthcare professionals when taking this medication. This medication helps improve blood sugar control and manage cardiovascular risk in patients with type 2 diabetes.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received diabetes medication, the recommended initial dose of this medicine when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients with allergic reactions to the main ingredient or excipients. Additionally, it should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Since it contains anhydrous lactose, it should not be used in patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients on dialysis should also not take this medication. Patients with decreased fluid volume or renal impairment should use this medication cautiously. This medication can cause hypotension or deterioration of kidney function, so it is essential to closely check fluid status and kidney function before and after administration. Particularly, elderly patients or those on diuretics are at high risk for hypotension and should be cautious. This medication contains Yellow No. 4 and Yellow No. 5 coloring agents, so it should be administered with caution in patients with allergies or hypersensitivity to these components. Taking this medication may increase the risk of genital infections or urinary tract infections. If symptoms of infection appear, immediate consultation with healthcare professionals is required. Hypoglycemia symptoms may occur; therefore, when taking it along with insulin or sulfonylureas, dose adjustment may be necessary to reduce the risk of hypoglycemia. Dehydration or hypotension symptoms may arise due to decreased fluid volume, so if symptoms of dehydration occur, the use of this medication should be temporarily discontinued, and a doctor should be consulted. Rarely, serious infections such as perineal necrosis can occur, so if there is pain, swelling, redness, or discomfort around the genital area, immediate medical attention should be sought. Pregnant or breastfeeding women are advised not to use this medication, and its use should be discontinued if pregnancy is confirmed. The safety and efficacy of this medication in children have not been sufficiently established, so its use is not recommended. In case of overdose, there are no specific antidotes, so it is important to receive appropriate treatment according to the symptoms. This medication does not significantly affect driving or operating machinery, but caution is needed due to the risk of hypoglycemia.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is recommended to keep it at room temperature between 1 to 30 degrees Celsius. Storing it this way will preserve the medication's effectiveness and ensure safe use.
Yellow, bilaterally convex, round film-coated tablet
28 tablets/box [14 tablets/PTP x 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Hanwha Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.